Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.50 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.50 |
| ▸ | CHRNG | P07510 | 1/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.50 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | CHRND | Q07001 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythro-Hydrobupropion SCHEMBL29465706 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL1227545 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL1226880 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL30252298 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL1226819 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL1229064 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL3320155 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL3320024 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL30252231 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL6429272 | 0.98 | SLC6A4 (0.63) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283334-A1 | Treatment of Viral Infections | BIOCOPEA, LTD. (GB) | 2012-11-08 | — | — | US | claimed |
| EP-1759701-B1 | Buproprion Metabolites for treating dementia and other cerebrovascular disorders | SEPRACOR INC (US) | 2010-12-22 | — | — | EP | claimed |
| EP-1259243-B2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC (US) | 2010-07-21 | — | — | EP | claimed |
| US-20100125070-A1 | Bupropion Metabolites and Methods of Their Synthesis and Use | FANG KEVIN QUN | 2010-05-20 | — | — | US | claimed |
| EP-1602369-B1 | Bupropion Metabolites for treating anxiety | SEPRACOR INC (US) | 2010-04-07 | — | — | EP | claimed |
| EP-1259243-B1 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC (US) | 2006-06-28 | — | — | EP | claimed |
| EP-1602369-A2 | Bupropion Metabolites and Methods of their Synthesis and Use | Sepracor, Inc. (US) | 2005-12-07 | — | — | EP | claimed |
| EP-1259243-A2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR, INC. (US) | 2002-11-27 | — | — | EP | claimed |
| US-20020052341-A1 | Bupropion metabolites and methods of their synthesis and use | SEPRACOR INC. | 2002-05-02 | — | — | US | claimed |
| US-6337328-B1 | TREATMENT OF SEXUAL DYSFUNCTION WITH 2-(3-CHLOROPHENYL)-2-HYDROXY-3,5,5-TRIMETHYL-MORPHOLINOL, 1-(3-CHLOROPHENYL)-2-((1,1-DIMETHYLETHANOL)AMINO)-1-PROPANOL, AND | SEPRACOR, INC. | 2002-01-08 | — | — | US | claimed |
| WO-2001062257-A2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC. (US) | 2001-08-30 | — | — | WO | claimed |
| US-20190331666-A1 | METHODS FOR DRUG DISCOVERY USING STEM CELL-DERIVED SCHWANN CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2019-10-31 | — | — | US | disclosed |
| US-20120283334-A1 | Treatment of Viral Infections | BIOCOPEA, LTD. (GB) | 2012-11-08 | — | — | US | disclosed |
| EP-1759701-B1 | Buproprion Metabolites for treating dementia and other cerebrovascular disorders | SEPRACOR INC (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-1259243-B2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-1259243-B1 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060058300-A1 | Intermediates of bupropion metabolites synthesis | SEPRACOR INC. | 2006-03-16 | — | — | US | disclosed |
| EP-1602369-A2 | Bupropion Metabolites and Methods of their Synthesis and Use | Sepracor, Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20020052341-A1 | Bupropion metabolites and methods of their synthesis and use | SEPRACOR INC. | 2002-05-02 | — | — | US | disclosed |
| US-6337328-B1 | TREATMENT OF SEXUAL DYSFUNCTION WITH 2-(3-CHLOROPHENYL)-2-HYDROXY-3,5,5-TRIMETHYL-MORPHOLINOL, 1-(3-CHLOROPHENYL)-2-((1,1-DIMETHYLETHANOL)AMINO)-1-PROPANOL, AND | SEPRACOR, INC. | 2002-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052341-A1 | Bupropion metabolites and methods of their synthesis and use | MAOB, MAOA, HTR5A | SLC6A4 5/4885SLC6A2 6/4885CYP2C19 170/4885 |
| US-20060058300-A1 | Intermediates of bupropion metabolites synthesis | MAOB, MAOA, SLC18A2 | SLC6A4 5/4885SLC6A2 7/4885CYP2C19 137/4885 |
| US-20100125070-A1 | Bupropion Metabolites and Methods of Their Synthesis and Use | MAOB, MAOA, HTR5A | SLC6A4 5/4885SLC6A2 6/4885CYP2C19 170/4885 |
| US-20120283334-A1 | Treatment of Viral Infections | ELANE, EPX, MAVS | SLC6A4 2547/4885SLC6A2 2689/4885CYP2C19 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.